Enhertu® Plus Pertuzumab Approved In The US

Reuters
2025.12.15 21:33
Dec 15 (Reuters) - AstraZeneca PLC (AZN.L) : * ENHERTU® (FAM-TRASTUZUMAB DERUXTECAN-NXKI) PLUS PERTUZUMAB APPROVED IN THE US AS FIRST NEW TREATMENT IN A DECADE FOR THE 1ST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER Source text: Further company coverage: (AZN.L)
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer